<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04473963</url>
  </required_header>
  <id_info>
    <org_study_id>CP-001/002</org_study_id>
    <nct_id>NCT04473963</nct_id>
  </id_info>
  <brief_title>FLOW-AF: A Study to Evaluate the Ablacon Electrographic FLOW EGF Technology</brief_title>
  <acronym>FLOW-AF</acronym>
  <official_title>A Randomized Controlled Study to Evaluate the Reliability of the Ablacon Electrographic FLOW (EGF) Algorithm Technology (Ablamap Software) to Identify AF Sources and Guide Ablation Therapy in Patients With Persistent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablacon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablacon, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the Ablacon Electrographic Flow (EGF) algorithm technology (Ablamap
      Software).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to evaluate the reliability of the Ablacon Electrographic Flow
      (EGF) algorithm technology (Ablamap Software) to identify atrial fibrillation sources and
      guide ablation therapy in patients with persistent atrial fibrillation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint: the ability to successfully ablate AF sources identified by the EGF algorithm as measured by EGF maps of the atria pre and post ablation to determine if there is a diminished or absence of the source.</measure>
    <time_frame>During the Procedure</time_frame>
    <description>Acute procedure success defined as the ability to successfully ablate AF sources identified by the EGF algorithm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint: Freedom from serious adverse events</measure>
    <time_frame>7 days</time_frame>
    <description>Freedom from serious adverse events related to the procedure through 7 days following the randomization procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoints: Consistency of sources</measure>
    <time_frame>Post procedure through 12 months</time_frame>
    <description>Consistency of sources identified by the Ablacon EGF algorithm between the randomization procedure and any applicable subsequent EGF-guided ablation procedures as assessed by remapping of the atria and the algorithm's ability to reproduce sources identified by a previous procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoints: Freedom from documented episodes of AF recurrence</measure>
    <time_frame>3-12 months</time_frame>
    <description>Freedom from documented episodes of atrial fibrillation recurrence following the blanking period (90 days post procedure through 12 months). Documentation will be from Holter recordings or EKGs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoints: Total number of EGF source ablations</measure>
    <time_frame>During the procedure</time_frame>
    <description>Total number of EGF source ablations (count number of ablations during the procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoints: Total time of EGF source ablations</measure>
    <time_frame>During the procedure</time_frame>
    <description>Total time of EGF source ablations (seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoints</measure>
    <time_frame>During the procedure</time_frame>
    <description>Total fluoroscopy time (min/sec)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoints</measure>
    <time_frame>During the procedure</time_frame>
    <description>Total fluoroscopy dose (mgy)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoints: Overall Procedure time</measure>
    <time_frame>During the procedure</time_frame>
    <description>Overall Procedure time (hours/minutes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation, Persistent</condition>
  <arm_group>
    <arm_group_label>EGF-Guided Ablation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to &quot;therapy&quot; will be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - No Ablation Therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects randomized to &quot;control&quot; will not be treated with cardiac ablation guided by the Ablacon Electrographic flow algorithm technology (Ablamap Software). The subjects will be cardioverted (as applicable) and the procedure will end.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablamap Software</intervention_name>
    <description>Subjects will receive cardiac ablation guided by the Ablamap software. The software will identify atrial fibrillation sources to help guide ablation therapy in patients with persistent atrial fibrillation. Subjects will undergo a cardioversion post ablation, as necessary.</description>
    <arm_group_label>EGF-Guided Ablation Therapy</arm_group_label>
    <other_name>Ablamap Electrographic Flow Algorithm Technology</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Suitable candidate for intra-cardiac mapping and ablation of atrial arrhythmias.

          2. Above eighteen (18) years of age or of legal age to give informed consent specific to
             state and national law.

          3. Subjects with a history of documented symptomatic, persistent or longstanding
             persistent atrial fibrillation &lt; 36 months.

          4. Subject agrees to comply with study procedures and be available (geographically
             stable) for follow-up visits for at least 12 months.

          5. Treatment of atrial fibrillation within the past 36 months with ablation therapy
             presenting with recurrent symptoms of AF.

        Exclusion Criteria:

          1. LA diameter &gt; 5.5 cm.

          2. Left ventricular ejection fraction (LVEF) &lt; 40%.

          3. Presence of intramural thrombus, tumor or abnormality that precludes vascular access,
             catheter introduction or manipulation.

          4. Coagulopathy, bleeding diathesis or suspected procoagulant state.

          5. Known allergies or intolerance to anticoagulant and antiplatelet therapies to be used
             in conjunction with the study or contrast sensitivity that cannot be adequately
             pre-treated prior to the ablation procedure.

          6. Positive pregnancy test results for female patients of childbearing potential or
             breast feeding.

          7. Acute or chronic medical condition that in the judgment of the investigator would
             increase risk to the patient or deem the patient inappropriate to participate in the
             study.

          8. Mitral valve stenosis and/or severe mitral regurgitation.

          9. Valvular atrial fibrillation.

         10. Prosthetic valves.

         11. NYHA Class IV.

         12. History of MI within 3 months prior to procedure.

         13. Atrial septal defect (ASD) or left atrial appendage (LAA) closure device.

         14. Atrial fibrillation from a reversible cause (e.g., surgery, hyperthyroidism,
             sarcoidosis or pericarditis).

         15. Life expectancy &lt; 12 months based on medical history or the medical judgement of the
             investigator.

         16. Implantable cardioverter defibrillators (ICD), cardiac resynchronization therapy (CRT)
             leads or pacemaker implant procedure.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Neuzil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator - Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tamas Szili-Torok, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator - The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Spitzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator - Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patty Hevey</last_name>
    <phone>650-222-3666</phone>
    <email>patty.hevey@ablacon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nemocnice Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <state>Czech Republic</state>
        <zip>150 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Neuzil, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

